Consent to the Distribution of New Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution inNew Zealand of the new medicines set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Purified Vi Capsular Polysaccharide of Salmonella typhi (Ty 2 strain) 0.025 mg per 0.5 ml dose Solution for injection Pasteur Merieux Serums et Vaccins S.A., Marcy L'Etoile, France Typhim Vi Lansoprazole 30 mg Capsule Lederle Laboratories, Cyanamid of Great Britain Limited, Gosport, Hampshire, England Zoton Oestradiol 3.9 mg Transdermal patch 3M Pharmaceuticals, Northridge, California, United States of America and 3M Pharmaceuticals, St Paul, Minnesota, United States of America Climara Oestradiol 7.8 mg Transdermal patch 3M Pharmaceuticals, Northridge, California, United States of America and 3M Pharmaceuticals, St Paul, Minnesota, United States of America Climara Forte Sodium bicarbonate 81.25 g/l (Cobe machine), sodium bicarbonate 66.0 g/l and sodium chloride 23.5 g/l (Gambro/Drake or Willock/Baxter machines) Dialysis solution Ajax Chemicals, Smithfield, New South Wales, Australia Concentrated Bicarbonate Haemodialysis Solution - Part/Component B Dorzolamide hydrochloride 2% (22.3 mg/ml equivalent to 20 mg dorzolamide) Ophthalmic solution Laboratoires Merck Sharp & Dohme-Chibret, Clementel, Clermont Ferrand, France Trusopt Lenograstim 263 mcg (33.6 million IU) Powder for injection Chugai Pharmaceuticals Company Limited, Ukima Plant, Tokyo, Japan Granocyte Famciclovir 250 mg Tablet SmithKline Beecham Pharmaceuticals, Manor Royal, Crawley, Sussex, England Famvir Dated this 11th day of November 1994. D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.